antifungals | CMAC

antifungals

The current place of echinocandins in the treatment and prophylaxis of invasive fungal infections

Invasive fungal infections continue to show steady growth among various patient populations, accompanied by high rates of both morbidity and attributive mortality. For the treatment of invasive mycoses, a few number of drugs are currently available, …

The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies

Posaconazole is a broad-spectrum triazole antifungal agent with potent activity against various fungi, including yeast and molds, including Mucorales, what makes a key difference with itraconazole and voriconazole. Clinical studies have demonstrated …

Review of the guidelines for the treatment and prevention of invasive candidiasis in newborns and children

nvasive infections caused by Candida species are the most common invasive fungal infections in children of different age groups. Premature neonates, especially newborns with low and extremely low birth-weight, have very high mortality rates, with the …

New Drug Formulations of Posaconazole: Brief Clinical Pharmacology Review

Posaconazole is a second generation triazole with a broad spectrum of activity, which first appeared on the market in 2005 in the form of a suspension for oral administration. Despite some progress made in the framework of clinical trials, the …

Fungal Infections Surveillance in Intensive Care Units

Invasive candidiasis is a common nosocomial infection with high attributable mortality among ICU patients. This study was performed to determine isolation rate of Candida spp. in cardiac surgical ICUs during the period of 2001–2007 and to assess …

New Drugs for the Treatment of Invasive Mycoses

Invasive mycoses becoming more and more important problem of the modern medicine that is reflecting the increasing number of immunocompromised patients population. Despite the fact that the main causative agents remain Candida albicans, Aspergillus …